Skip to main content

thor-707

·Code: THOR-707

thor-707: developed by 1 company · 5 clinical trials tracked.

thor-707 evidence translation

What we can confirm

5 tracked trials

What it means

Source-backed records connect thor-707 to THOR; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could thor-707 → THOR affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Development Pipeline (1)
CompanyPhase
Synthorx, Inc. (THOR)
Solid tumors
Preclinical
Clinical Trials (5)

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer

NCT05104567·Phase 2·SNY
Completed

Primary endpoint: Cohort A: Objective Response Rate (ORR)

Interventionalopen138 enrolledStarted 2021-12Completion 2024-0929 sites · Belgium, Chile, China, France…Sanofi

Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma

NCT05179603·Phase 2·SNY
Terminated

Primary endpoint: Complete Response Rate (CRR)

Interventionalopen14 targetStarted 2021-12Completion 2024-098 sites · Argentina, Chile, SpainSanofi

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma

NCT04914897·Phase 2·SNY
Terminated

Primary endpoint: Cohorts A1 and A2: Objective Response Rate (ORR)

Interventionalopen106 targetStarted 2021-09Completion 2024-1035 sites · Argentina, Australia, Chile, France…Sanofi

A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers

NCT04913220·Phase 1/Phase 2·SNY
Terminated

Primary endpoint: All Cohorts: Objective Response Rate (ORR)

Interventionalopen46 targetStarted 2021-07Completion 2025-0224 sites · Australia, Chile, France, Germany…Sanofi

An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors

NCT04009681·Phase 1/Phase 2·SNY
Terminated

Primary endpoint: Rate of Dose-Limiting Toxicities (DLTs)- Cohorts A, B, C, and D

Interventionalopen175 targetStarted 2019-06Completion 2025-1224 sites · Argentina, Australia, Chile, Singapore…Synthorx, Inc, a Sanofi company

Frequently asked questions

Who is developing thor-707?

thor-707 is being developed by Synthorx, Inc..

How many clinical trials involve thor-707?

BioSniper tracks 5 clinical trials involving thor-707.